Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

Figure 2 Correlation analysis. A: Correlation between tumor necrosis alpha and progression free survival in all metastatic colorectal cancer (mCRC) patients (n = 17) (r_s = -0.52, P = 0.033); B: Correlation between transforming growth factor alpha and progression free survival in all mCRC patients (n = 17) (r_s = -0.52, P = 0.038); C: Correlation between tumor necrosis alpha and transforming growth factor alpha in all mCRC patients (n = 17) (r_s = 0.53, P = 0.028). P < 0.05 was considered the statistical significance. Each dot represents the value of one patients. Transforming growth factor alpha and tumor necrosis alpha are expressed as a concentration (pg/mL). Progression free survival is expressed in months. PFS: Progression free survival; TNF-α: Tumor necrosis alpha; TGF-β: Transforming growth factor alpha.